Press

Filament Health Announces Participation in Project Solace

Jul 28 • 2 min read

Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical‐stage natural psychedelic drug development company, today announced its participation in Project Solace, the world’s largest medical psilocybin access and data project. Project Solace is led by TheraPsil in collaboration with Drug Science. Filament has enrolled in the project as a Health Canada-licensed producer of psilocybin. “We…

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa

Jul 28 • 4 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it has launched a multi-centre, double-blind randomised controlled phase II clinical trial investigating the efficacy of COMP360 psilocybin, administered with psychological support, in people with anorexia nervosa. The phase II clinical trial…

Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Industry Leader as VP R&D and Growth

Jul 27 • 4 min read

Braxia Scientific Corp., (CSE: BRAX | OTC: BRAXF | FWB: 4960), a medical research company with clinics providing innovative ketamine and psilocybin treatments for people living with depression and related mental health disorders, is pleased to announce the addition of Jason Wolkove, Chief Information Officer and Daniel Herrera, Vice President, Research & Development and Growth….

CAMH receives first Canadian federal (CIHR) grant to study psilocybin

Jul 27 • 4 min read

The Centre for Addiction and Mental Health (CAMH) has just been awarded Canada’s first federal grant to study psilocybin—the chemical component of “magic mushrooms”—with regard to its effect on treatment-resistant depression. More specifically, researchers will explore whether experiencing psilocybin’s psychedelic effects are required for it to have antidepressant effects. “There has been a growing interest and body…

COMPASS Pathways to announce second quarter 2022 financial results on August 4, 2022

Jul 26 • 2 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2022, and provide an update on recent business developments on 4 August 2022. The management team will host a conference call at…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435